NovoCure NVCR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$71.14M-107% | -$24.5M+62.8% | -$37.27M-21.9% | -$40.14M-20.3% | -$34.32M+11.5% | ||
| $4.12M+24.0% | $4.22M+35.9% | $3.66M+49.0% | $3.44M+20.5% | $3.33M+18.1% | ||
| $63.01M+113% | $19.82M-68.4% | $29.32M-6.5% | $26.14M-17.9% | $29.55M-13.3% | ||
| $712K-68.5% | $1.94M+416% | $230K-48.9% | $424K+203% | $2.26M+1,065% | ||
| $2.78M-29.5% | $1.98M+158% | -$886K+53.2% | $629K+133% | $3.94M-15.2% | ||
| -$5.12M+68.8% | $8.44M-58.5% | $24.83M+233% | $2.11M-77.9% | -$16.42M+10.0% | ||
| -$219K+90.4% | $513K+172% | $789K+165% | $5.92M+1,796% | -$2.27M-240% | ||
| -$2.04M+20.8% | -$4.37M— | -$2.49M-30.6% | -$1.41M+71.1% | -$2.58M-120% | ||
| -$2.84M-153% | -$2.64M-115% | -$2.43M-58.1% | $920K+150% | -$1.12M+36.5% | ||
| -$2.62M+60.7% | -$3.75M+43.9% | -$6.4M+5.0% | -$6.46M+5.7% | -$6.65M-23.7% | ||
| -$13.52M+62.1% | -$18M-422% | $20.57M+98.3% | -$15.94M-827% | -$35.67M-13.0% | ||
| $5.15M-51.4% | $4.9M-45.2% | $5.66M-47.1% | $5.49M-52.1% | $10.61M-10.0% | ||
| $110M-8.3% | $560M+229% | $185M-2.6% | $420M+163% | $120M-53.5% | ||
| $97.1M-16.2% | $218.78M+19.4% | $107.91M-36.2% | $378.53M-27.6% | $115.86M— | ||
| $7.75M+220% | $336.33M+1,614% | $71.44M+601% | $35.99M+110% | -$6.47M-103% | ||
| $0— | $0— | $99.98M— | $0-100% | $0— | ||
| $0— | $560.95M— | $0— | $0-100% | $0— | ||
| $0— | $1.52M-22.6% | $0— | $2.14M-2.3% | $0— | ||
| -$166K-103% | -$559.49M-20,938% | $100.52M+100,417% | $2.39M-97.3% | $5.25M+2,363% | ||
| -$130K-157% | —— | -$22K-125% | $265K+444% | $227K+505% | ||
| -$6.07M+83.5% | -$241.25M-944% | $192.51M+827% | $22.7M+108% | -$36.66M-117% | ||
| $4.96M+87.6% | $5.24M+88.6% | $2.84M-4.1% | $2.67M+35.9% | $2.65M+132,150% | ||
| -$3.88M-178% | $8.43M+31.6% | $3.43M-48.3% | $13.84M+84.5% | $4.97M+70.6% | ||
| -$2.62M+60.7% | -$3.75M+43.9% | -$6.4M+5.0% | -$6.46M+5.7% | -$6.65M-23.7% | ||
| $712K-68.5% | $1.94M+416% | $230K-48.9% | $424K+203% | $2.26M+1,065% | ||
| -$477K-1,073% | —— | -$890K-277% | -$1.37M-110% | $49K+108% | ||
| -$828K-110% | $23.46M+35.0% | -$3.58M+33.9% | $10.45M-6.0% | $8.61M+163% | ||
| -$219K+90.4% | $513K+172% | $789K+165% | $5.92M+1,796% | -$2.27M-240% | ||
| -$2.84M-153% | -$2.64M-115% | -$2.43M-58.1% | $920K+150% | -$1.12M+36.5% | ||
| $97.1M-16.2% | $218.78M+19.4% | $107.91M-36.2% | $378.53M-27.6% | $115.86M— | ||
| $556K— | —— | —— | —— | $0— | ||
| $792K+213% | $516K-63.6% | $370K+84.1% | $404K+0.7% | $253K-76.2% | ||
| $998K-95.8% | $1.58M+43.2% | $2.68M+254% | $1.62M+198% | $23.49M+8,230% | ||
| -$3.88M-178% | $8.43M+31.6% | $3.43M-48.3% | $13.84M+84.5% | $4.97M+70.6% | ||
| -$18.67M+59.7% | -$22.9M-84.8% | $14.92M+4,960% | -$21.42M-62.7% | -$46.28M-6.7% | ||
| -$18.67M+59.7% | -$22.9M-84.8% | $14.92M+4,960% | -$21.42M-62.7% | -$46.28M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.